Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)
Status:
Recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed
to respond or relapsed after prior therapy, with a platelet count <30,000/µL. Patient will be
randomly assigned in 2 groups with two dose levels of SKI-O-703 200mg BID, 400 mg BID, and
placebo; administered orally twice a day.